Ftse Mib
35.398,82
-0,03%
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
66.983,25
-0,15%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Shattuck Labs Inc (STTK) Shattuck Labs Inc (STTK) Notizie

STTK

Shattuck Labs (STTK)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:STTK
DataOraFonteTitoloSimboloCompagnia
14/05/202422:15GlobeNewswire Inc.Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the EuNASDAQ:STTKShattuck Labs Inc
14/05/202422:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STTKShattuck Labs Inc
02/05/202413:05GlobeNewswire Inc.Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:STTKShattuck Labs Inc
09/04/202422:05GlobeNewswire Inc.Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:STTKShattuck Labs Inc
01/04/202413:00GlobeNewswire Inc.Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:STTKShattuck Labs Inc
08/03/202423:29Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:STTKShattuck Labs Inc
06/03/202422:42Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:STTKShattuck Labs Inc
04/03/202413:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STTKShattuck Labs Inc
04/03/202413:00GlobeNewswire Inc.Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of DirectorsNASDAQ:STTKShattuck Labs Inc
29/02/202422:41Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:STTKShattuck Labs Inc
29/02/202422:23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:STTKShattuck Labs Inc
29/02/202422:05GlobeNewswire Inc.Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business HighlightsNASDAQ:STTKShattuck Labs Inc
26/02/202413:00GlobeNewswire Inc.Shattuck Labs Announces Participation in Upcoming March ConferencesNASDAQ:STTKShattuck Labs Inc
14/02/202411:06PR Newswire (US)Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion ProteinsNASDAQ:STTKShattuck Labs Inc
13/02/202412:00GlobeNewswire Inc.Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory DiseasesNASDAQ:STTKShattuck Labs Inc
02/02/202422:32Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:STTKShattuck Labs Inc
01/02/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:STTKShattuck Labs Inc
24/01/202422:31Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:STTKShattuck Labs Inc
08/01/202413:00GlobeNewswire Inc.Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024NASDAQ:STTKShattuck Labs Inc
04/01/202422:05GlobeNewswire Inc.Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:STTKShattuck Labs Inc
22/12/202322:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:STTKShattuck Labs Inc
21/12/202314:00GlobeNewswire Inc.Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded WarrantsNASDAQ:STTKShattuck Labs Inc
13/12/202315:00AllPennyStocks.comSmall Cap Steals The Show With Wild Premarket ActionNASDAQ:STTKShattuck Labs Inc
13/12/202312:00GlobeNewswire Inc.Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) PatiNASDAQ:STTKShattuck Labs Inc
05/12/202322:15GlobeNewswire Inc.Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation DatNASDAQ:STTKShattuck Labs Inc
14/11/202315:00GlobeNewswire Inc.Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:STTKShattuck Labs Inc
09/11/202313:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:STTKShattuck Labs Inc
09/11/202312:00GlobeNewswire Inc.Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:STTKShattuck Labs Inc
06/11/202315:28GlobeNewswire Inc.Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023NASDAQ:STTKShattuck Labs Inc
02/11/202314:01GlobeNewswire Inc.Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 AnnualNASDAQ:STTKShattuck Labs Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:STTK

La tua Cronologia

COIN
SSUSD
Sharder
OKEX
TNBUSDT
AMEX
IHY
VanEck International Hig...
NASDAQ
ISLN
BOV
ITUBT323
ITUBT323 Ex:30,91
USOTC
POTRF
Soperior Fertilizer (CE)
ASX
ARK
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network